Active substance
Results for the substance tisagenlecleucel
1 result
About this active substance
Tisagenlecleucel is a cellular gene therapy used for the treatment of certain types of cancer, including acute lymphoblastic leukemia (ALL) in children and young adults and large B-cell lymphoma in adults. It involves the use of the patient's T cells, which are genetically modified to recognize and destroy cancer cells.
The treatment is administered as a single intravenous infusion after a procedure to collect and modify the patient's T cells. It is used in cases where other treatments have failed.
Patients should be closely monitored to detect potential side effects, such as cytokine release syndrome (CRS) or neurological toxicity. It is important that the treatment is administered in a specialized center.
Common side effects include fever, fatigue, nausea, and decreased blood cell counts. In rare cases, severe reactions such as severe CRS or encephalopathy may occur. Patients should be informed of these risks before starting treatment.
The treatment is administered as a single intravenous infusion after a procedure to collect and modify the patient's T cells. It is used in cases where other treatments have failed.
Patients should be closely monitored to detect potential side effects, such as cytokine release syndrome (CRS) or neurological toxicity. It is important that the treatment is administered in a specialized center.
Common side effects include fever, fatigue, nausea, and decreased blood cell counts. In rare cases, severe reactions such as severe CRS or encephalopathy may occur. Patients should be informed of these risks before starting treatment.